Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
Blood Cancer Journal
|
January 23, 2016
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
A-L Gagez, E Tuaillon, R Cezar, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery
|
March 25, 2014
Editor's choice--hybrid treatment of thoracic, thoracoabdominal, and abdominal aortic aneurysms: a multicenter retrospective study
E Rosset, S Ben Ahmed, G Galvaing, et al.
Blood
|
October 6, 2001
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
M Leporrier, S Chevret, B Cazin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
P Feugier, A Van Hoof, C Sebban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2007
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma
A Plonquet, C Haioun, J-P Jais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2023
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
A S Cottereau, L Rebaud, J Trotman, et al.
Leukemia
|
July 11, 2008
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab
J-P Jais, C Haioun, T J Molina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA
A Trebouet, T Marchand, R Lemal, et al.
Blood
|
July 14, 2017
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study
R-O Casasnovas, L Ysebaert, C Thieblemont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial
T Petrella, C Copie-Bergman, J Brière, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
Blood Cancer Journal
|
January 23, 2016
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
A-L Gagez, E Tuaillon, R Cezar, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery
|
March 25, 2014
Editor's choice--hybrid treatment of thoracic, thoracoabdominal, and abdominal aortic aneurysms: a multicenter retrospective study
E Rosset, S Ben Ahmed, G Galvaing, et al.
Blood
|
October 6, 2001
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
M Leporrier, S Chevret, B Cazin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
P Feugier, A Van Hoof, C Sebban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2007
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma
A Plonquet, C Haioun, J-P Jais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2023
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
A S Cottereau, L Rebaud, J Trotman, et al.
Leukemia
|
July 11, 2008
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab
J-P Jais, C Haioun, T J Molina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA
A Trebouet, T Marchand, R Lemal, et al.
Blood
|
July 14, 2017
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study
R-O Casasnovas, L Ysebaert, C Thieblemont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial
T Petrella, C Copie-Bergman, J Brière, et al.
Page
of 8